Lilly Diabetes Alliance, Boehringer Ingelheim to present study results at ADA’s Scientific Sessions

The presentation of 35 abstracts will demonstrate the breadth and depth of the Boehringer Ingelheim (BIPI) and Eli Lilly and Company (NYSE: LLY) Diabetes alliance portfolio at the 75th American Diabetes Association's (ADA) Scientific Sessions® in Boston, June 5-9.

"With growing numbers of people being diagnosed with diabetes, there is tremendous need for ongoing clinical research to ensure treatment options and approaches are available to meet patients' diverse needs," said Thomas Seck, M.D., vice president, Clinical Development and Medical Affairs - Metabolism at Boehringer Ingelheim. "As part of our commitment to the diabetes community, the BI-Lilly Diabetes alliance will present an array of product, disease state and patient-physician survey data that help address the needs of adults with diabetes."

Highlighted presentations and posters include:

Empagliflozin/Metformin Data

Sunday, June 7, 2015: 12 p.m. – 2 p.m. EDT – General Poster Session

  • Initial Combinations of Empagliflozin and Metformin (EMPA+MET) in Patients with Type 2 Diabetes (T2DM) (Presenting Author: Hadjadj, S.) [119-LB]

Empagliflozin plus immediate-release metformin hydrochloride fixed-dose combination is an investigational compound being studied for the treatment of adults with T2D. Data on this combination will be discussed in a late-breaker poster presentation.

IntroDia™ Survey Data

Sunday, June 7, 2015: 12 p.m. – 2 p.m. EDT – General Poster Session

  • Physician-Patient Communication At Prescription of an Additional Oral Agent for Type 2 Diabetes (T2D): Link Between Key Conversation Elements, Physician Empathy and Patient Outcomes - Insights From the Global IntroDia™ Study (Presenting Author: Capehorn, M.) [63-LB]

IntroDia™ is the largest global patient and physician survey ever conducted that focuses on early conversations about T2D – providing insights into how physicians and patients interact at important moments of the diabetes treatment journey. New results from the survey will be presented as a late-breaker poster presentation.

Tradjenta® (linagliptin) Data

Sunday, June 7, 2015: 12 p.m. – 2 p.m. EDT - General Poster Session

  • Safety and Efficacy of Linagliptin in Patients with Type 2 Diabetes (T2D) and Coronary Artery Disease (CAD): Analysis Of Pooled Incident Investigator Reported Events From Phase 3 Clinical Trials (Presenting Author: Leiter, L.) [1246-P]

Linagliptin, marketed as Tradjenta® (linagliptin) 5 mg tablets in the U.S., is a DPP-4 inhibitor, which works by increasing hormones that stimulate the pancreas to produce more insulin and stimulate the liver to produce less glucose. Data will be presented as a poster presentation.

SOURCE Eli Lilly and Company; Boehringer Ingelheim Pharmaceuticals, Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post
You might also like... ×
Researchers unlock the key to clearly identifying diseased beta cells in type 2 diabetes